In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin
Authors:
Open Access
- 19 June 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 62 (4) , 766-768
Abstract
We determined the in vitro activity of retapamulin, a novel pleuromutilin antibiotic, against 664 Staphylococcus aureus isolates from the UK, including many resistant to fusidic acid and/or highly resistant to mupirocin. MICs were determined on Mueller–Hinton agar in accordance with the CLSI guidelines. Susceptibility was categorized using CLSI criteria, where available; otherwise the European Committee for Antimicrobial Susceptibility Testing (EUCAST)/BSAC criteria were used (for mupirocin and fusidic acid). Mutations in the rplC gene, which encodes ribosomal protein L3, were sought by PCR and DNA sequencing. The S. aureus included 488 (73%) methicillin-resistant isolates (oxacillin MICs >2 mg/L), 336 isolates (51%) resistant to fusidic acid (MICs >1 mg/L) and 254 (38%) with high-level mupirocin resistance (MICs >256 mg/L); 103 (16%) isolates were resistant both to fusidic acid and to high levels of mupirocin. Retapamulin inhibited 663 (99.9%) isolates at ≤0.25 mg/L. A single methicillin-resistant S. aureus isolate, also with high-level mupirocin resistance, required a retapamulin MIC of 2 mg/L, but its reduced susceptibility to retapamulin was not associated with any mutation in ribosomal protein L3. Retapamulin demonstrated excellent activity in vitro against S. aureus isolates, irrespective of their level of resistance to other antibacterials. These results support the EUCAST epidemiological cut-off value for retapamulin of ≤0.5 mg/L against S. aureus.Keywords
This publication has 11 references indexed in Scilit:
- First Report of cfr -Mediated Resistance to Linezolid in Human Staphylococcal Clinical Isolates Recovered in the United StatesAntimicrobial Agents and Chemotherapy, 2008
- Linezolid and Tiamulin Cross-Resistance in Staphylococcus aureus Mediated by Point Mutations in the Peptidyl Transferase CenterAntimicrobial Agents and Chemotherapy, 2008
- Stepwise Exposure of Staphylococcus aureus to Pleuromutilins Is Associated with Stepwise Acquisition of Mutations in rplC and Minimally Affects Susceptibility to RetapamulinAntimicrobial Agents and Chemotherapy, 2007
- Acquisition of a natural resistance gene renders a clinical strain of methicillin‐resistantStaphylococcus aureusresistant to the synthetic antibiotic linezolidMolecular Microbiology, 2007
- BSAC standardized disc susceptibility testing method (version 6)Journal of Antimicrobial Chemotherapy, 2007
- The Cfr rRNA Methyltransferase Confers Resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A AntibioticsAntimicrobial Agents and Chemotherapy, 2006
- Interaction of Pleuromutilin Derivatives with the Ribosomal Peptidyl Transferase CenterAntimicrobial Agents and Chemotherapy, 2006
- Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulinMolecular Microbiology, 2004
- A Fusidic Acid-Resistant Epidemic Strain of Staphylococcus aureus Carries the fusB Determinant, whereas fusA Mutations Are Prevalent in Other Resistant IsolatesAntimicrobial Agents and Chemotherapy, 2004
- The pleuromutilin drugs tiamulin and valnemulin bind to the RNA at the peptidyl transferase centre on the ribosomeMolecular Microbiology, 2001